Clinical Trials
4
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
1
25.0%
Not yet recruiting
2
50.0%
Recruiting
1
25.0%
No approval data available
- The STAMINA lifestyle intervention reduced deterioration in quality of life by as much as one-third in men receiving androgen deprivation therapy for prostate cancer, researchers reported in The Lancet Oncology. - In the 700-patient UK trial across 15 NHS hospitals, more than 80% of participants attended scheduled supervised exercise sessions over the 12-month study period. - Economic modelling showed the program costs well below standard NHS thresholds for cancer interventions and is expected to remain cost-effective for up to a decade. - Nuffield Health has launched a Cancer Activity Programme based on STAMINA, committing to fund 50,000 places by 2030 with planned expansion to breast and bowel cancer.
- Iridex Corporation has enrolled the first patient in the independent DAME trial, which will evaluate whether adding subthreshold MicroPulse laser treatment to anti-VEGF therapy can reduce injection burden for severe diabetic macular edema patients. - The UK-based study will enroll 264 patients across over 20 clinical sites and is designed to demonstrate equivalence in visual outcomes between combination therapy and anti-VEGF monotherapy over 24 months. - The trial aims to address current treatment limitations of frequent anti-VEGF injections, which are expensive, burdensome to patients and healthcare systems, and can cause patient anxiety with potential sight-threatening complications. - The study builds on the successful DIAMONDS trial, which demonstrated safety and effectiveness of subthreshold MicroPulse laser in patients with less severe diabetic macular edema.
• myTomorrows has expanded its clinical trial search platform by incorporating the ISRCTN registry, providing comprehensive access to WHO-endorsed trial databases including clinicaltrials.gov and EudraCT. • The platform's new AI assistant reduces trial pre-screening time by 90% through automated patient profile matching and offers rapid insights into drug mechanisms, efficacy, and safety. • The enhanced platform has already facilitated connections between over 14,000 patients and 2,100 physicians for clinical trials across 40 countries, with particular benefits for UK-based research post-Brexit.
- The MS-STAT2 trial, a phase 3 study, evaluated simvastatin's effectiveness in slowing disability progression in patients with non-active secondary progressive multiple sclerosis (SPMS). - Results showed simvastatin did not significantly reduce disability progression compared to placebo over a 48-month period (HR 1.13, 95% CI 0.91-1.39, P = 0.26). - While simvastatin was safe and well-tolerated, the trial's primary and secondary outcomes did not demonstrate a benefit for SPMS, despite promising phase 2 results. - Researchers emphasize the trial's value in understanding progressive MS and enabling future large-scale clinical trials for emerging treatments.
- The COVID-19 pandemic catalyzed unprecedented changes in clinical trials, with remote monitoring evolving from an optional feature to an essential requirement for study continuation. - Clinical trial recruitment saw remarkable success during the pandemic, with studies like the RECOVERY Trial enrolling over 2,000 participants across 16 NHS sites in just three weeks. - While the pandemic accelerated certain patient-centric practices, the urgency of COVID-19 research sometimes compromised patient engagement, revealing areas for improvement in the clinical trial ecosystem.
- Major UK medical research funders allocate less than 1% of their budgets to rare disease research, despite these conditions consuming 10% of the NHS specialized services budget. - Research into rare diseases like alkaptonuria (AKU) has proven valuable for understanding common conditions such as osteoarthritis, demonstrating their broader scientific importance. - Public awareness initiatives like the French Telethon, which raised €94 million in 2011, show the potential for increased rare disease funding through effective advocacy campaigns.
